-
EP3520811
European procedure
Extract from the Register of European Patents
EP About this file: EP3520811
| EP3520811 - METHODS FOR INCREASING FORCED EXPIRATORY VOLUME IN ASTHMATICS USING BENRALIZUMAB [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 05.11.2021 Database last updated on 09.04.2026 | |
| Former | The patent has been granted Status updated on 27.11.2020 | ||
| Former | Grant of patent is intended Status updated on 08.07.2020 | ||
| Former | Request for examination was made Status updated on 14.02.2020 | ||
| Former | The application has been published Status updated on 05.07.2019 | Most recent event Tooltip | 05.11.2021 | No opposition filed within time limit | published on 08.12.2021 [2021/49] | Applicant(s) | For all designated states Astrazeneca AB 151 85 Södertälje / SE | [2019/32] | Inventor(s) | 01 /
WARD, Christine c/o MedImmune LLC One Medimmune Way Gaithersburg, Maryland 20878 / US | 02 /
ROSKOS, Lorin c/o MedImmune LLC One Medimmune Way Gaithersburg, Maryland 20878 / US | 03 /
WANG, Bing c/o Medimmune LLC One Medimmune Way Gaithersburg, Maryland 20878 / US | 04 /
RAIBLE, Donald 317 Lenape Drive Berwyn, Pennsylvania 19312 / US | [2019/32] | Representative(s) | AstraZeneca Intellectual Property Eastbrook House Shaftesbury Road Cambridge CB2 8BF / GB | [N/P] |
| Former [2019/32] | AstraZeneca Milstein Building Granta Park Cambridge CB21 6GH / GB | Application number, filing date | 19158446.5 | 07.08.2014 | [2019/32] | Priority number, date | US201361864948P | 12.08.2013 Original published format: US 201361864948 P | [2019/32] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3520811 | Date: | 07.08.2019 | Language: | EN | [2019/32] | Type: | B1 Patent specification | No.: | EP3520811 | Date: | 30.12.2020 | Language: | EN | [2020/53] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 13.05.2019 | Classification | IPC: | A61K39/00, A61K39/395, G01N33/48, A61P11/06 | [2019/32] | CPC: |
C07K16/2866 (EP,CN,US);
A61K39/39541 (CN);
A61K39/395 (RU);
A61K45/06 (EP,US);
A61P11/06 (EP,RU);
A61P43/00 (EP);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/12] |
| Former [2019/32] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Extension states | BA | 07.02.2020 | ME | 07.02.2020 | Title | German: | VERFAHREN ZUR ERHÖHUNG DES FORCIERTEN EXSPIRATORISCHEN VOLUMENS BEI ASTHMATIKERN MIT BENRALIZUMAB | [2019/32] | English: | METHODS FOR INCREASING FORCED EXPIRATORY VOLUME IN ASTHMATICS USING BENRALIZUMAB | [2019/32] | French: | PROCÉDÉ POUR AUGMENTER LE VOLUME D'EXPIRATION FORCÉE CHEZ DES ASTHMATIQUES À L'AIDE DE BENRALIZUMAB | [2019/32] | Examination procedure | 05.02.2020 | Amendment by applicant (claims and/or description) | 07.02.2020 | Examination requested [2020/12] | 07.02.2020 | Date on which the examining division has become responsible | 09.07.2020 | Communication of intention to grant the patent | 18.11.2020 | Fee for grant paid | 18.11.2020 | Fee for publishing/printing paid | 18.11.2020 | Receipt of the translation of the claim(s) | Parent application(s) Tooltip | EP14836725.3 / EP3033104 | Divisional application(s) | EP20208316.8 / EP3875487 | EP25150773.7 / EP4579236 | EP25191983.3 | Opposition(s) | 01.10.2021 | No opposition filed within time limit [2021/49] | Fees paid | Renewal fee | 21.06.2019 | Renewal fee patent year 03 | 21.06.2019 | Renewal fee patent year 04 | 21.06.2019 | Renewal fee patent year 05 | 02.09.2019 | Renewal fee patent year 06 | 31.08.2020 | Renewal fee patent year 07 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A] WO2013066780 (MEDIMMUNE LLC et al.) | [A] WO2008143878 (MEDIMMUNE LLC et al.) | [A] MICHEL LAVIOLETTE ET AL: "Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 132, no. 5, 16 July 2013 (2013-07-16), AMSTERDAM, NL, pages 1086 - 1096.e5, XP055277773, ISSN: 0091-6749, DOI: 10.1016/j.jaci.2013.05.020 DOI: http://dx.doi.org/10.1016/j.jaci.2013.05.020 | [A] MERCK: "Asthma Severity and Control Monitoring Guide", 1 January 2007 (2007-01-01), XP055341967, Retrieved from the Internet | [A] GHAZI AASIA ET AL: "Benralizumab--a humanized mAb to IL-5R[alpha] with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma", EXPERT OPINION ON BIOLOGICAL THERAPY, INFORMA HEALTHCARE, UK, vol. 12, no. 1, 1 January 2012 (2012-01-01), pages 113 - 118, XP009159038, ISSN: 1744-7682, DOI: 10.1517/14712598.2012.642359 DOI: http://dx.doi.org/10.1517/14712598.2012.642359 | [A] N. A. MOLFINO ET AL: "Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor", CLINICAL & EXPERIMENTAL ALLERGY, vol. 42, no. 5, 1 May 2012 (2012-05-01), pages 712 - 737, XP055026155, ISSN: 0954-7894, DOI: 10.1111/j.1365-2222.2011.03854.x DOI: http://dx.doi.org/10.1111/j.1365-2222.2011.03854.x | [T] EUGENE R BLEECKER ET AL: "Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting &bgr;2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial", LANCET, vol. 388, no. 10056, 1 October 2016 (2016-10-01), AMSTERDAM, NL, pages 2115 - 2127, XP055342068, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(16)31324-1 DOI: http://dx.doi.org/10.1016/S0140-6736(16)31324-1 | by applicant | WO2013066780 | US2010291073 | US6018032 | MASOLI M ET AL., ALLERGY, vol. 59, 2004, pages 469 - 78 | LEDERLE F ET AL., ARCH INT MED, vol. 147, 1987, pages 2201 - 03 | KRISHNAN J ET AL., AJRCCM, vol. 170, 2004, pages 1281 - 85 | JAMES A., CURR OPIN PULM MED, vol. 77, no. 1, 2005, pages 1 - 6 | JANSON C; HERALA M., RESP MED, vol. 86, no. 2, 1992, pages 101 - 104 | ULRIK C; FREDERICKSEN J., CHEST, vol. 108, 1995, pages 10 - 15 | RESTREPO R; PETERS J., CURR OPIN PULM MED, vol. 14, 2008, pages 13 - 23 | BELLIDO-CASADO J ET AL., ARCH BRONCONEUMOL, vol. 46, no. 11, 2010, pages 587 - 93 | GREEN R ET AL., LANCET, vol. 360, 2002, pages 1715 - 21 | HALDAR P ET AL., NEJM, vol. 360, 2009, pages 973 - 84 | BUSSE W ET AL., JACI, vol. 125, 2010, pages 1237 - 1244 | HANKINSON ET AL., AM J RESPIR CRIT CARE MED, vol. 159, 1999, pages 179 - 87 | SORKNESS ET AL., JAPPL PHYSIOL, vol. 104, 2008, pages 394 - 403 | SORKNESS ET AL., J APPL PHYSIOL, vol. 104, 2008, pages 394 - 403 | "Am JRespir Crit Care Med.", vol. 161, 2000, AMERICAN THORACIC SOCIETY, pages: 309 - 329 |